|
EP
PerMed is launching the first Joint Transnational Call (JTC2024) for
proposals on “Identification or Validation of Targets for
Personalised Medicine Approaches (PMTargets)”. In total, 39 funding
organisations of 24 countries and 10 European national regions
participate in this call with a budget of over 45 Mio€. This call is
cofunded by the European Union.
With
its first JTC, EP PerMed aims to fund research that fosters the
identification or validation of targets for personalised medicine
(PM) approaches. The overall objectives of the JTC2024 are to
- Support research
projects in human health aiming at identifying or validating
targets for personalised medicine approaches in combination with
development of companion biomarkers or other markers to allow
for monitoring of treatment outcomes and patient stratification;
- Encourage and enable
interdisciplinary collaborations by combining pre-clinical and
clinical research in translational projects, and multi-actor
research by engaging a range of other relevant disciplines such
as bioinformatics/health informatics/data research, ELSA
research, implementation research or health economics research
connected to the proposed research topic, including end-user
perspective analysis to empower the implementation of PM; and
- Encourage
cross-sectorial collaborations, by including the private sector
(e.g. SMEs, small and medium-sized enterprises), industry, as
well as regulatory/HTA agencies and patient organisations.
The
core of each application must be the identification or validation of
a target for personalised medicine approaches in combination with
companion biomarker research. In addition, the consortia can address
accompanying research if this is necessary for the identification or
validation of the target and if appropriate to the development status
of the project. EP PerMed
strongly encourages the active involvement of end-users in the
proposed research projects.
Depending
on the development phase of the research, projects can focus on the
following stages:
- Stage 1: Identification of
novel targets for the development of a concrete and feasible PM
approach, based on a clearly circumscribed biological/clinical
hypothesis, in combination with companion biomarker research.
Applicants are advised to use existing clinical data as a basis
for target identification.
- Stage 2: Development or
validation of already known but not yet established targets for
a PM approach, in combination with accompanying biomarker
research. This includes target validation in vitro and in animal
models (proof-of-principle studies), early pharmacological and
toxicity tests and, if feasible, exploratory clinical studies to
demonstrate clinical applicability (proof-of-concept studies).
Exclusion:
Research focussing only on new biomarker discovery. Projects
submitted to the JTC2024 focussing on the identification of new
biomarkers as the sole purpose of the research are out of the scope.
Stages
are not mutually exclusive. They define the overall scope of the
JTC2024 to which all proposals must comply.
Research
projects in all disease areas are encouraged. Consortia are required to start from a
relevant clinical (unmet) need and to include activities that support
a comprehensive and efficient uptake of the developed PM approach in
clinical practice, with the aim that “Today’s research is tomorrow’s
healthcare”.
Please
refer to the Call Text of the JTC2024 for further information and
definitions.
Important
dates:
- Opening of the online
submission tool: 12 January 2024
- Information day
introducing the JTC2024 to the research community: January 15,
2024, 14:00-16:00 (CET) (registration link will be available
soon)
- Submission deadline
for pre-proposals: 05 March 2024, 17:00 CET
- Submission deadline
for full-proposals: 20 June 2024, 17:00 CEST
JTC2024 information are
available here
|
